98. 好酸球性消化管疾患 Eosinophilic gastrointestinal disease Clinical trials / Disease details
臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03656380 (ClinicalTrials.gov) | March 20, 2019 | 30/8/2018 | Mepo for EoE Study | A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms | EoE;Eosinophilic Esophagitis | Drug: Mepolizumab 300 mg;Drug: Mepolizumab 100 mg;Other: Placebo | University of North Carolina, Chapel Hill | GlaxoSmithKline;University of Utah;Northwestern University;MNGI Digestive Health, P.A. | Completed | 16 Years | 75 Years | All | 66 | Phase 2 | United States |
| 2 | NCT00358449 (ClinicalTrials.gov) | September 11, 2006 | 27/7/2006 | Intravenous Mepolizumab In Children With Eosinophilic Esophagitis | A Randomized, Double-blind, Parallel Group Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Mepolizumab (SB240563)(0.55mg/kg, 2.5mg/kg or 10mg/kg) in Pediatric Subjects With Eosinophilic Esophagitis, Aged 2 to 17 Years (Study MEE103219) | Oesophagitis, Eosinophilic | Drug: mepolizumab | GlaxoSmithKline | NULL | Completed | 2 Years | 17 Years | All | 84 | Phase 2 | United States;Australia;Canada;United Kingdom |
| 3 | EUCTR2005-006074-10-GB (EUCTR) | 15/06/2006 | 07/02/2006 | A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years - Mepolizumab in paediatric eosinophilic oesophagitis | A randomized, double-blind, parallel group clinical trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous mepolizumab (SB240563) (0.55mg/kg, 2.5mg/kg or 10mg/kg) in pediatric subjects with eosinophilic esophagitis, aged 2 to 17 years - Mepolizumab in paediatric eosinophilic oesophagitis | Eosinophilic oesophagitis | Product Name: Mepolizumab Product Code: SB-240563 INN or Proposed INN: Mepolizumab | GlaxoSmithKline Research & Development Ltd. | NULL | Not Recruiting | Female: yes Male: yes | 72 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom | ||
| 4 | NCT00266565 (ClinicalTrials.gov) | December 2001 | 15/12/2005 | Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome | A Phase I/II Study of the Effect of Intravenous Anti-IL-5 (Mepolizumab) SB 240563 on the Outcome and Management of Hypereosinophilic Syndromes | Hypereosinophilic Syndromes;Eosinophilic Gastroenteritis;Churg-Strauss Syndrome;Eosinophilic Esophagitis | Drug: Mepolizumab | Children's Hospital Medical Center, Cincinnati | NULL | Completed | 18 Years | 65 Years | All | 24 | Phase 1/Phase 2 | United States |